NCT05978284

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

A Phase 1/2 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.

Conditions

• Small Cell Lung Cancer
• Neuroendocrine Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	ZG006	ZG006 will be administered as an intravenous (IV) infusion.

Timeline

• Start date: 2023-10-27
• Primary completion: 2026-09-01
• Completion: 2026-10-01
• First posted: 2023-08-07
• Last updated: 2026-01-05

Locations

1 site across 1 country: China